New Xultophy® (IDegLira) Phase 3b Study Showed Statistically Significant HbA1c Reduction, Body Weight Change and Lower Rate of Hypoglycaemia Versus Insulin Glargine
Boston (ots/PRNewswire) - - 166-OR This material is intended for medical non-UK media only. For journalistic assessment and preparation before publication. New phase 3b findings showed adults with type 2 diabetes treated with Xultophy(R) (IDegLira), a once-daily, single-injection combination of insulin degludec and ...